Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality, day 60 13% Improvement Relative Risk Mortality, day 30 12% De Santis et al. Conv. Plasma for COVID-19 RCT LATE Is late treatment with convalescent plasma beneficial for COVID-19? RCT 107 patients in Brazil No significant difference in mortality De Santis et al., Emerging Infectious Diseases, doi:10.3201/eid2803.212299 Favors conv. plasma Favors control
High-Dose Convalescent Plasma for Treatment of Severe COVID-19
De Santis et al., Emerging Infectious Diseases, doi:10.3201/eid2803.212299
De Santis et al., High-Dose Convalescent Plasma for Treatment of Severe COVID-19, Emerging Infectious Diseases, doi:10.3201/eid2803.212299
Mar 2022   Source   PDF  
  All Studies   Meta
RCT 110 hospitalized patients in Brazil, showing no significant difference in outcomes with high-dose convalescent plasma.
risk of death, 13.2% lower, RR 0.87, p = 0.67, treatment 11 of 36 (30.6%), control 25 of 71 (35.2%), NNT 21, day 60.
risk of death, 12.3% lower, RR 0.88, p = 0.81, treatment 8 of 36 (22.2%), control 18 of 71 (25.4%), NNT 32, day 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
De Santis et al., 31 Mar 2022, Randomized Controlled Trial, Brazil, peer-reviewed, 23 authors, average treatment delay 9.0 days.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Abstract: RESEARCH High-Dose Convalescent Plasma for Treatment of Severe COVID-19 Gil C. De Santis, Luciana Correa Oliveira, Pedro M.M. Garibaldi, Carlos E.L. Almado, Julio Croda, Ghislaine G.A. Arcanjo, Érika A.F. Oliveira, Adriana C. Tonacio, Dante M. Langhi Jr., José O. Bordin, Renato N. Gilio, Leonardo C. Palma, Elaine V. Santos, Simone K. Haddad, Benedito P.A. Prado Jr., Marjorie Cornejo Pontelli, Rogério Gomes, Carlos H. Miranda, Maria Auxiliadora Martins, Dimas T. Covas, Eurico Arruda, Benedito A.L. Fonseca, Rodrigo T. Calado To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients with severe COVID-19 who were within 10 days of initial symptom onset were eligible. Patients in the CCP group received 3 daily doses of CCP (600 mL/d) in addition to standard treatment; control patients received standard treatment only. Primary outcomes were death rates at days 30 and 60 of study randomization. Secondary outcomes were ventilator-free days and hospital-free days. We enrolled 107 patients: 36 CCP and 71 control. At day 30, death rates were 22% for CCP and 25% for the control group; at day 60, rates were 31% for CCP and 35% for control. Needs for invasive mechanical ventilation and durations of hospital stay were similar between groups. We conclude that high-dose CCP transfused within 10 days of symptom onset provided no benefit for patients with severe COVID-19. Author affiliations: University of São Paulo, São Paulo, Brazil (G.C. De Santis, L.C. Oliveira, E.V. Santos, S.K. Haddad, B.P.A. Prado Jr., D.T. Covas, R.T. Calado); Hospital Estadual de Serrana, Serrana, Brazil (P.M.M. Garibaldi, C.E.L. Almado); Hospital Regional do Mato Grosso do Sul, Campo Grande, Brazil (J. Croda); Fundação Oswaldo Cruz, Campo Grande (J. Croda); Universidade do Mato Grosso do Sul, Campo Grande (J. Croda, G.G.A. Arcanjo); Hospital São Camilo, São Paulo (É.A.F. Oliveira, A.C. Tonacio, D.M. Langhi Jr.); Universidade Federal de São Paulo, São Paulo (D.M. Langhi Jr., J.O. Bordin); Hospital Estadual de Américo Brasiliense, Américo Brasiliense, Brazil (R.N. Gilio); Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, Brazil (L.C. Palma); Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, São Paulo (M.C. Pontelli, R. Gomes, C.H. Miranda, M.A. Martins, E. Arruda, B.A.L. Fonseca) DOI: 548 C linical signs and symptoms of coronavirus disease (COVID-19) are pleomorphic, varying from none (asymptomatic) to life-threatening. Typical signs/ symptoms are fever, dry cough, dyspnea, fatigue, myalgia, anosmia, and ageusia (1). Radiography or computed tomography of the chest usually reveals bilateral pulmonary ground-glass opacifications, mainly in posterior and peripheral areas of the lungs (2). The most common laboratory test alterations are lymphopenia and elevated serum concentrations of inflammatory biomarkers and D-dimers (3). Risk factors for unfavorable outcomes are older age, concurrent conditions, and perhaps but of lesser importance, blood type A (4,5). Thus far, there is no consensual agreement about specific therapy for this disease, despite several attempts to develop one (3,6). More recently, antiviral agents such as MK-4482/EIDD-2801 and PF-07321332 seem to be promising (7,8). In the past, passive antibody transfer by plasma or serum..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop